Date: February 23rd 2009


 

BioTrinity 2009 - Oxford, April 2-3, 2009

UK's Premier Biotechnology and Investment Conference

Over 50 biotech and medtech investors from the US and Europe will be partnering at BioTrinity 2009 Oxford (April 2-3), including some of the biggest names in the industry: Atlas, Abingworth, Avlar, MVM, and Excalibur and corporate venturers such as GSK’s SR One, Novo A/S, Genzyme Ventures, Takeda Research Investments, and MPHVM.  Early stage investors Spark, Esperante, Rainbow, Oxford Capital and Oxford Technology will also be in force meeting start-ups, as well as the newly formed Albion Ventures LLP. Investors attending have a total of $32bn under management.

Four key facts about BioTrinity 2009 - Oxford

 10 of world's top 20 global pharma represented
 200 companies already confirmed from 12 countries
 Partnering is live and takes place in private rooms
 Gala Dinner at an Oxford University College

BioTrinity 2009 will also feature plenaries and panel discussions from the successful entrpreneurs John Burt, David Knowles and Ken Powell who built up and sold UK biotechnology companies Thiakis, Piramed and Arrow and returned nearly $500m of value to their investors. 

BioTrinity 2009 will face the challenges of the current climate head-on with key issues addressed by industry leaders. Dealing with successful deal making in the current climate, BioTrinity will draw on the experiences of key industry pharma licensing figures, including Nigel Sheail, VP Global Head of Licensing at Roche, Esteban Pombo-Villar, Head of Strategic Alliance Management at Novartis and Kate Burt, Director, Transactions at GSK, as well as Ian Nicholson, CEO of Chroma Therapeutics and Jane Dancer, Vice President Business Development at Cellzome.

Dealing with successful fundraising in the current climate, BioTrinity will draw on the experiences of key VCs including Regina Hodits, Partner at Atlas Venture, which recently closed its $283m Fund VIII, as well as corporate venturers Graeme R Martin, CEO, Takeda Research Investments, Martin Edwards, Senior Partner, Novo A/S, Allison Robbins, Senior Associate, Genzyme Ventures, Sam Fazelli, Head of European Equity Research, Piper Jaffray and David Mott, Investment Director at Oxford Capital Partners who will be among over 50 investor delegates expected to attend this year.

BioTrinity unites the UK’s biotech industry, and provides an ideal platform for US and European companies to partner with pharma, meet investors and European companies in the most beautiful city in England, just 1 hours' drive from Heathrow International Airport. The updated programme for BioTrinity has now been published online and can be downloaded: online

...........................................................................................

Who else is attending BioTrinity 2009?

   GSK

Novartis

Merck

   Roche

Genzyme

Bristol Myers-Squibb

   Eli Lilly

Takeda

Shire Pharma

   Teva Pharma

(OSI) Pharmaceuticals

EUSA Pharma

   Abingworth Mgmt

Esperante Ventures

Takeda Research Inv., Inc.

   Novo A/S

Atlas Venture

MPHVM

   SR One

Excalibur Group

H2O Venture Partners

   Oxford Capital Partners

Oxford Tech. Management

Piper Jaffray

   H2O Venture Partners

Genzyme Ventures

Avlar BioVentures

   MVM Life Science Prtnrs.

Andy Richards

The Wellcome Trust

   Rainbow Seed Fund

Albion Ventures

SPARK Ventures

   ETV Capital

Edmond de Rothschld Inv Prt

Orion Healthcare Equity

See who else is attending...

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"As a direct result of our focused partnering meetings we introduced proteros to potential clients at BioTrinity 2008 which we are pleased to report resulted in several new opportunities and one of which has developed into a substantial business relationship". Gordon J Woodrow, VP at Proteros biostructures GmbH

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

Register online now! www.biotrinity.com

Register online now at www.biotrinity.com

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

OBN 

 

© 2006-2009 OBN

<< Previous: BioTrinity - Keep me informed Key Industry Issues Dealt with at BioTrinity 2009

| Archive Index |

Next: BioTrinity - Keep me informed Record Registrations - Only Four Weeks Left to Register (Partnering is Live) >>

(archive rss , atom )

this list's archives:


This list is for those who wish to stay informed about developments in the BioTrinity conference programme, to find out when there are new announcements, when the online partnering service and company profiles are online, presentation or sponsorship opportunities, and most importantly when registration opens!

BioTrinity - BioPartnering Meeting and Company Showcase
April 2nd-3rd 2009 - Oxford

Subscribe/Unsubscribe on BioTrinity - Keep me informed

* Required



Powered by Dada Mail 3.0.0 beta 3 - 05/19/08
Copyright © 1999-2008, Simoni Creative.

Go back to Visit the BioTrinity website